Habil Khorakiwala’s turnaround of Wockhardt began amid near bankruptcy, including payment defaults to bondholders and troubled manufacturing units. After surviving the company’s worst crises, the focus has shifted to a single blockbuster antibiotic drug hailed as the biggest breakthrough after penicillin. If it scales, Khorakiwala could re-enter the top league again.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
